First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

PURPOSE: To assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab (JNJ-63723283), a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced/refractory solid tumors in the phase 1/2 LUC1001 study. METHODS: In phase 1, pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Felip, Enriqueta, Moreno, Victor, Morgensztern, Daniel, Curigliano, Giuseppe, Rutkowski, Piotr, Trigo, José Manuel, Calvo, Aitana, Kowalski, Dariusz, Cortinovis, Diego, Plummer, Ruth, Maio, Michele, Ascierto, Paolo A., Vladimirov, Vladimir I., Cervantes, Andres, Zudaire, Enrique, Hazra, Anasuya, T’jollyn, Huybrecht, Bandyopadhyay, Nibedita, Greger, James G., Attiyeh, Edward, Xie, Hong, Calvo, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956549/
https://www.ncbi.nlm.nih.gov/pubmed/35298698
http://dx.doi.org/10.1007/s00280-022-04414-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956549/
https://www.ncbi.nlm.nih.gov/pubmed/35298698
http://dx.doi.org/10.1007/s00280-022-04414-6

Ejemplares similares